Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD

白细胞介素-21工程改造通过CEBPD增强NK细胞对抗胶质母细胞瘤的活性

阅读:2
作者:Mayra Shanley,May Daher,Jinzhuang Dou,Sufang Li,Rafet Basar,Hind Rafei,Merve Dede,Joy Gumin,Jezreel Pantaleόn Garcίa,Ana Karen Nunez Cortes,Shan He,Corry M Jones,Sunil Acharya,Natalie W Fowlkes,Donghai Xiong,Sanjay Singh,Hila Shaim,Samantha Claire Hicks,Bin Liu,Abhinav Jain,Mohammad Fayyad Zaman,Qi Miao,Ye Li,Nadima Uprety,Enli Liu,Luis Muniz-Feliciano,Gary M Deyter,Vakul Mohanty,Patrick Zhang,Scott E Evans,Elizabeth J Shpall,Frederick F Lang,Ken Chen,Katayoun Rezvani

Abstract

Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM. We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple in vivo models, IL-21 NK cells were superior to IL-15 NK cells both in terms of safety and long-term anti-tumor activity, with locoregionally administered IL-15 NK cells proving toxic and ineffective at tumor control. IL-21 NK cells displayed a unique chromatin accessibility signature, with CCAAT/enhancer-binding proteins (C/EBP), especially CEBPD, serving as key transcription factors regulating their enhanced function. Deletion of CEBPD resulted in loss of IL-21 NK cell potency while its overexpression increased NK cell long-term cytotoxicity and metabolic fitness. These results suggest that IL-21, through C/EBP transcription factors, drives epigenetic reprogramming of NK cells, enhancing their anti-tumor efficacy against GBM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。